<DOC>
	<DOCNO>NCT01068743</DOCNO>
	<brief_summary>To demonstrate bioequivalence 2.5 mg saxagliptin/850 mg metformin fix dose combination ( FDC ) tablet relative 2.5 mg saxagliptin tablet 850 mg metformin ( Glucophage Marketed Merck-Serono ) tablet co-administered healthy subject fast fed condition .</brief_summary>
	<brief_title>Bioequivalence Study Fixed Dose Combination 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative 2.5 mg Onglyza 850 mg Glucophage Tablets Co-Administered</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Men woman age 18 55 inclusive Healthy subject determine clinically significant deviation normal medical history , physical examination , electrocardiogram ( ECGs ) , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m^2 , inclusive . BMI = weight ( kg ) / [ height ( ) ] ^2 Any significant acute chronic medical illness Current recent ( within 3 month ) gastrointestinal disease Any major surgery within 4 week study drug administration History allergy dipeptidyl peptidaseIV ( DPP4 ) inhibitor relate compound History allergy intolerance metformin similar acting agent Prior exposure saxagliptin Prior exposure metformin within 3 month study drug administration Estimated creatinine clearance ( Clcr ) &lt; 80 mL/min use Cockcroft Gault formula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>